Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docarpamine for refractory ascites in cirrhosis
ACTRN12620000211965Phase 2Terminated
- Sponsor
- Martin Pharmaceuticals
- Start
- May 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of docarpamine in Cirrhosis (2 arms), sponsored by Martin Pharmaceuticals. Primary endpoint: Total volume of ascitic fluid. Started May 2020; status: terminated.
02
Drugs
docarpamine
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on ACTRN12620000211965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000211965.